Overcame Barriers- Anticancer Agent S-1 Capsule (S-1) Received Reimbursement for Treatment of Gastric Cancer

Overcame Barriers- Anticancer Agent S-1 Capsule (S-1) Received Reimbursement for Treatment of Gastric Cancer

2016.12.13 最新消息

...

More

TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer

TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer

2016.12.13 最新消息

...

More

TTY Biopharm received an exclusive license from Taiho Pharmaceutical to sell an anticancer drug in Taiwan market

TTY Biopharm received an exclusive license from Taiho Pharmaceutical to sell an anticancer drug in Taiwan market

2016.10.18 最新消息

...

More

TTY Biopharm (4105 TT) and PharmaMar (MSE:PHM) jointly announce that PharmaMar submits Aplidin® for treatment of MM

TTY Biopharm (4105 TT) and PharmaMar (MSE:PHM) jointly announce that PharmaMar submits Aplidin® for treatment of MM

2016.9.22 最新消息

...

More

TTY and the international company will jointly develop the overseas market for the Liposome product

TTY and the international company will jointly develop the overseas market for the Liposome product

2016.7.5 最新消息

...

More

Overview of Drug Evaluation and Registration

Overview of Drug Evaluation and Registration

2016.7.5 最新消息

...

More

PharmaEngine Announces MM-398 (PEP02) in Combination with 5-FU/LV Result

PharmaEngine Announces MM-398 (PEP02) in Combination with 5-FU/LV Result

2014.5.1 最新消息

...

More

TOP